Background There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family
blocker) with erlotinib (a reversible EGFR tyrosine kinase inhibitor), as second-line treatment
for patients with advanced squamous cell carcinoma of the lung. Methods We did this open-
label, phase 3 randomised controlled trial at 183 cancer centres in 23 countries worldwide.
We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had …

Background LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib
and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma
(SCC) of the lung. We report the final overall survival (OS) and safety analyses of LUX-Lung
8 and investigate the characteristics of patients who achieved long-term benefit (≥ 12
months' treatment). Methods LUX-Lung 8 (NCT01523587) enroled patients between March
2012 and January 2014 and this final analysis had a data cut-off of March 2018. Eligible …